Nom du produit:2-Amino-5-formylpyridine

IUPAC Name:6-aminopyridine-3-carbaldehyde

CAS:69879-22-7
Formule moléculaire:C6H6N2O
Pureté:96%
Numéro de catalogue:CM174092
Poids moléculaire:122.13

Unité d'emballage Stock disponible Prix($) Quantité
CM174092-5g in stock ưƄŔ
CM174092-10g in stock ŢƄƄ
CM174092-25g in stock ƞȎź

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:69879-22-7
Formule moléculaire:C6H6N2O
Point de fusion:-
Code SMILES:O=CC1=CN=C(N)C=C1
Densité:
Numéro de catalogue:CM174092
Poids moléculaire:122.13
Point d'ébullition:
N° Mdl:MFCD09757481
Stockage:Keep in dark place, inert atmosphere, store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Abemaciclib
Lilly announced the five-year results of a pre-planned analysis of Phase 3 MonarchE study, which evaluated two years of adjuvant Verzenio® (Abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence. Abemaciclib is the first and only CDK4/6 inhibitor approved for the treatment of node-positive, high-risk early breast cancer (EBC) patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.